Pharma Tips

Pfizer to create separate, internal, global Innovative & Value businesses

By: Pharma News | Views: 1197 | Date: 02-Aug-2013

Pfizer Inc. (NYSE: PFE) has announced plans to move forward to internally separate its commercial operations into three business segments, two of which will include Innovative business lines and a third which will include the Value business line. Each of the three segments will include developed markets and emerging markets. The changes will be implemented in January 2014 in countries that do not require a consultation with works councils or unions, and will be implemented in countries that require consulta

Pfizer to create separate, internal, global Innovative and Value businesses
 

Pfizer Inc. (NYSE: PFE) has announced plans to move forward to internally separate its commercial operations into three business segments, two of which will include Innovative business lines and a third which will include the Value business line. Each of the three segments will include developed markets and emerging markets. The changes will be implemented in January 2014 in countries that do not require a consultation with works councils or unions, and will be implemented in countries that require consultation after the successful conclusion of those processes. Beginning with the first-quarter 2014 financial results, the company will provide financial transparency for each of these three business segments, which will include a 2014 baseline management view of profit and loss for each segment.

One of the Innovative business segments will be led by Geno Germano, Group President, Innovative Products Group. It will generally include products across multiple therapeutic areas that are expected to have market exclusivity beyond 2015. The therapeutic areas include Inflammation and Immunology, CV/Metabolic, Neuroscience and Pain, Rare Diseases and Women's /Men's Health.

The other Innovative business segment will include Vaccines, Oncology and Consumer Healthcare and will be led by Amy Schulman, Group President, Vaccines, Oncology and Consumer Healthcare. Each of these businesses will operate as a separate global business and require distinct specialization in terms of the science, talent, and market approach required to deliver value to consumers and patients.

 

 

The Value business segment will be led by John Young, Group President, Value Products Group. This group will include products that generate strong, consistent cash flow, and will be positioned to provide patients access to effective, lower-cost, high-value treatments. In addition to products that have lost market exclusivity, it will generally include mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets, biosimilars and current and future established products collaborations, such as our existing partnerships with Mylan in Japan, Teuto in Brazil and Hisun in China.

 

 

Olivier Brandicourt will lead the transition from the current Emerging Markets organization to the regional structure that will be established for each of the three business segments.

 

 

In connection with the changes we are announcing today, Douglas Lankler, currently Chief Compliance and Risk Officer, will become General Counsel, and Rady Johnson, currently Senior Vice President and Associate General Counsel, will become Chief Compliance and Risk Officer.

 

All leadership changes will be effective January 1, 2014.

 

 

Ian Read, Chairman and Chief Executive Officer, stated, "This represents the next steps in Pfizer’s journey to further revitalize our innovative core, enhance the value of our consumer and off-patent established brands and maximize the use of our capital to create value for Pfizer and our shareholders.

 

 

"Through this evolution, we will enable greater independence and focus for the Innovative and Value businesses. Our new commercial operating model will provide each business with an enhanced ability to respond to market dynamics, greater visibility and focus, and distinctive capabilities optimized to deliver value to patients and shareholders in the coming years."

 

About Pfizer Inc.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Previous Page Next Page

People Searching On This Page:
  • reproductive system
  • male reproductive system
  • endocrine system

Related Pages


Pfizer to buy Hospira at enterprise value of $17 bn

Pfizer to buy Hospira at enterprise value of $17 bn

News | Pharma Companies
Date:
10-Feb-2015  Views: 825

Pharmaceuticals firm Pfizer Inc will acquire Hospira Inc, a leading provider of injectable drugs, infusion technologies and biosimilars, at a total en ...
Mylan Inc to acquire Famy Care's businesses for $800 mn

Mylan Inc to acquire Famy Care's businesses for $800 mn

News | Pharma Companies
Date:
05-Feb-2015  Views: 899

Mylan Inc will acquire certain businesses of Mumbai-based Famy Care Ltd, a specialty women's health care company, for a total consideration of $800 mi ...
Cipla, Pfizer, Sanofi cut prices of diabetic, cardiac drugs

Cipla, Pfizer, Sanofi cut prices of diabetic, cardiac drugs

News | Pharmaceutical Drugs
Date:
12-Sep-2014  Views: 902

Cipla, Pfizer and Sanofi have started supplying drugs capped in the anti-diabetic and cardio-vascular segments as per the July 10 NPPA notification wh ...
Executives Planning & Warehouse Jobs in Pfizer

Executives Planning & Warehouse Jobs in Pfizer

Jobs | PPIC Jobs | Goa
Date:
18-Jul-2014  Views: 3820

Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and ...
Job for PharmD, JD, Ph.D as Global Regulatory Strategist in Pfizer

Job for PharmD, JD, Ph.D as Global Regulatory Strategist in Pfizer

Jobs | Regulatory Affair
Date:
18-May-2014  Views: 4113

Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

6  + 9 =     
Comments
People Searched About:
Reproductive System   |   Male Reproductive System   |   Endocrine System   |  
Google : 106 times | Yahoo : 15 times | Bing : 10 times |